Comparative Pharmacology
Head-to-head clinical analysis: INDERAL versus METOPROLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERAL versus METOPROLOL.
INDERAL vs Metoprolol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; competitively blocks beta-1 receptors in the heart, decreasing heart rate, contractility, and cardiac output; reduces renin release from kidneys.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
Metoprolol tartrate: Initial 50 mg PO BID or 100 mg PO daily; maintenance 100-450 mg/day in divided doses. Metoprolol succinate (extended-release): Initial 25-100 mg PO once daily; maintenance 100-400 mg once daily.
None Documented
None Documented
Clinical Note
moderateMetoprolol + Digoxin
"Metoprolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateMetoprolol + Digitoxin
"Metoprolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateMetoprolol + Deslanoside
"Metoprolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateMetoprolol + Acetyldigitoxin
"Metoprolol may increase the bradycardic activities of Acetyldigitoxin."
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
3–7 hours for metoprolol; prolonged in poor CYP2D6 metabolizers (up to 8–16 hours). Clinical context: dosing interval typically twice daily (immediate-release) or once daily (extended-release).
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Primarily hepatic metabolism (CYP2D6) producing inactive metabolites; renal excretion accounts for <5% unchanged. Fecal elimination minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker